General
Preferred name
BI00645435
Synonyms
BIX 02565 ()
BIX-02565 ()
BIX02565 ()
cpd 24 ()
P&D ID
PD012470
CAS
1311367-27-7
Tags
drug candidate
probe
free of charge
available
Drug indication
Discovery agent
Probe info
Probe type
experimental probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
3
No orthogonal probes found
Similar probes
1
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
BIX 02565 is an inhibitor that can be used as a tool compound to study the activity of the AGC family protein kinase RSK2. Known off-target effects have been determined against LRRK2, PRKD1/2/3 and RET kinases.
(GtoPdb)
COMMENT
The compound has potential off-target activity on LRRK2 and PRKD1. The patent review (PMID: 27410995) describes how binding to the adrenergic receptors may result in a lethal decrease of heart rate which is also noted in the primary publications listed 10.1124/jpet.111.189365. Compound 15 in the same reference is offered as a better in vivo tool compound because it does not bind adrenergic receptors 10.1124/jpet.111.189365. Aug 4 2021 - 9:32pm; This compound is not recommended for use in vivo due to cardiotoxicity relating to its off-target effects on adrenergic receptors. Compounds with no off-target cardiotoxicity were later derived from this compound through additional medicinal chemistry. They would be more appropriate for use in vivo. Aug 4 2021 - 9:39pm
DESCRIPTION
BIX 02565 is a highly potent inhibitor of the three human ribosomal S6 kinase (RSK) isoforms. RSK is implied in regulation of cardiac cells and there are scientific data that support the notion of a potential role in heart failure secondary to myocardial infarction. The inhibitor, generated against human RSK, shows cross-reactivity to mouse and rat RSK. The overall balanced profile makes BIX 02565 an attractive compound to study the role of RSK kinases.
(opnMe Portal)
MOA
Inhibitor
(Chemical Probes.org)
DESCRIPTION
BIX 02565, a RSK2 inhibitor, has also been found to significanltly influence sorts of adrenergic receptor subtypes involved in ascular tone and cardiac function. IC50: 1.1 nM (RSK2)
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
Chemical Probes.org
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
CZ-OPENSCREEN Bioactive Library
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
High-quality chemical probes
Kinase Chemogenomic Set (KCGS)
Kinase Inhibitors (best-in-class)
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
opnMe Portal
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
14
Molecular Weight
458.24
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
4
cLogP
3.89
TPSA
84.19
Fraction CSP3
0.35
Chiral centers
1.0
Largest ring
7.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
RSK2
LRRK2
RPS6KA6, NUAK2, STK17A, STK17B, RSK2, LRRK2, PRKD1
Ribosomal S6 Kinase (RSK)
RSK kinases
RPS6KA3
Known off targets
LRRK2, PRKD1/2/3, RET
Kinase group
AGC
Pathway
PI3K/Akt/mTOR signaling
Autophagy
MAPK
MAPK/ERK Pathway
MOA
S6 Kinase
Orthogonal probe
BI-D1870
Solubility
DMSO: ≥ 20.75 mg/mL
Target class
Protein kinase
Recommended Cell Concentration
100 nM
Source data
